NASDAQ:DYN

Dyne Therapeutics (DYN) Stock Price, News & Analysis

$25.44
+0.57 (+2.29%)
(As of 04/23/2024 ET)
Today's Range
$24.83
$26.33
50-Day Range
$22.41
$29.18
52-Week Range
$6.40
$30.27
Volume
807,667 shs
Average Volume
961,172 shs
Market Capitalization
$2.19 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.43

Dyne Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.14 Rating Score
Upside/​Downside
47.1% Upside
$37.43 Price Target
Short Interest
Bearish
16.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Dyne Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$44.69 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.25) to ($3.14) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.39 out of 5 stars

Medical Sector

278th out of 909 stocks

Pharmaceutical Preparations Industry

119th out of 423 stocks

DYN stock logo

About Dyne Therapeutics Stock (NASDAQ:DYN)

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

DYN Stock Price History

DYN Stock News Headlines

This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Dyne Therapeutics Appoints John Cox As CEO To Succeed Joshua Brumm
Dyne Therapeutics Announces CEO Transition
Dyne Therapeutics (NASDAQ: DYN)
DYN Apr 2024 30.000 put
DYN Apr 2024 22.500 call
DYN Apr 2024 30.000 call
See More Headlines
Receive DYN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/05/2024
Today
4/23/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DYN
Employees
141
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$37.43
High Stock Price Target
$56.00
Low Stock Price Target
$22.00
Potential Upside/Downside
+47.1%
Consensus Rating
Buy
Rating Score (0-4)
3.14
Research Coverage
7 Analysts

Profitability

Net Income
$-235,940,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.49 per share

Miscellaneous

Free Float
68,279,000
Market Cap
$2.19 billion
Optionable
Optionable
Beta
0.95
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives


DYN Stock Analysis - Frequently Asked Questions

Should I buy or sell Dyne Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dyne Therapeutics in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DYN shares.
View DYN analyst ratings
or view top-rated stocks.

What is Dyne Therapeutics' stock price target for 2024?

7 brokers have issued 1-year price objectives for Dyne Therapeutics' shares. Their DYN share price targets range from $22.00 to $56.00. On average, they predict the company's share price to reach $37.43 in the next twelve months. This suggests a possible upside of 47.1% from the stock's current price.
View analysts price targets for DYN
or view top-rated stocks among Wall Street analysts.

How have DYN shares performed in 2024?

Dyne Therapeutics' stock was trading at $13.30 at the beginning of the year. Since then, DYN stock has increased by 91.3% and is now trading at $25.44.
View the best growth stocks for 2024 here
.

Are investors shorting Dyne Therapeutics?

Dyne Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 8,080,000 shares, an increase of 18.5% from the March 15th total of 6,820,000 shares. Based on an average daily volume of 1,710,000 shares, the short-interest ratio is presently 4.7 days. Currently, 16.2% of the company's stock are short sold.
View Dyne Therapeutics' Short Interest
.

When is Dyne Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our DYN earnings forecast
.

How were Dyne Therapeutics' earnings last quarter?

Dyne Therapeutics, Inc. (NASDAQ:DYN) issued its quarterly earnings data on Tuesday, March, 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.92) by $0.17.

When did Dyne Therapeutics IPO?

Dyne Therapeutics (DYN) raised $175 million in an IPO on Thursday, September 17th 2020. The company issued 10,300,000 shares at $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel served as the underwriters for the IPO.

Who are Dyne Therapeutics' major shareholders?

Dyne Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Vivo Capital LLC (1.90%), Wasatch Advisors LP (0.48%), Vida Ventures Advisors LLC (0.47%), Raymond James & Associates (0.20%), Arcadia Investment Management Corp MI (0.04%) and Allspring Global Investments Holdings LLC (0.00%). Insiders that own company stock include Dirk Kersten, Jason P Rhodes, Jonathan Mcneill, Joshua T Brumm, Oxana Beskrovnaya, Richard William Scalzo, Susanna Gatti High, Venture Fund Xi LP Atlas and Wildon Farwell.
View institutional ownership trends
.

How do I buy shares of Dyne Therapeutics?

Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DYN) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners